Creative and Flexible Structures
We invest across all therapeutic categories, modalities and geographies. Our focus is primarily on commercial-stage and near commercial-stage healthcare products, though in certain cases we invest in earlier stage opportunities.
Oberland Capital’s broad suite of flexible financing solutions includes monetization of royalty streams, acquisition of future product revenues, creation of project-based financing structures, and investments in traditional debt and equity. Our team excels in developing and implementing novel, non-dilutive transaction structures in situations involving significant complexity.
Our target investment size ranges between $50 million and $300 million, and we can execute significantly larger transactions. With the capacity to invest at meaningful scale, we are well-positioned to support our partners’ organic and inorganic growth.
We have a long-term investment horizon so that our partners can focus on what they do best—successfully develop and commercialize technologies that address medical unmet needs.
- Royalty Monetizations
- Royalty-Backed Securities
- Revenue Interests
- Traditional Debt
- Project-Based Structures
- Hybrid Structures
Oberland Capital specializes in royalty monetizations where we provide capital upfront or as a series of milestones in exchange for the rights to future royalties, providing our partners the opportunity to immediately unlock the value of their intellectual property. Monetizing all or a portion of existing or future royalty streams delivers capital to drive continued innovation in the industry, whether to fund new research, finance commercial expansion, or simply diversify and manage risk.
As an alternative to dilutive forms of capital, we work with our partners to provide loans that are collateralized by royalties, license agreements, and intellectual property. Principal and interest payments on the loan are derived solely from royalties received and are typically non-recourse to the royalty holder. Once the loan is repaid in full, the royalty owner retains rights to all future royalties.
With revenue interest financing, Oberland Capital provides capital to healthcare companies in exchange for a royalty on future revenues from one or more products. This type of financing is non-dilutive to shareholders and can be an attractive option for healthcare companies looking for an alternative to traditional forms of financing.
Oberland Capital offers long-term credit facilities to healthcare companies. These facilities are structured in a manner that best fits the needs of our partners.
We support companies pursuing late-stage clinical trials with project-based financing. In this type of structure, Oberland Capital may receive milestone payments and royalties depending on the successful progress of the clinical trials. This form of financing allows companies to accelerate R&D timelines and pursue a broader set of development projects.
Oberland Capital employs structures combining traditional equity or debt instruments or project-based structures with the purchase of royalties or revenue interests. These hybrid structures allow for tailored solutions to meet our partners’ specific capital requirements.